Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
To know about the assumptions considered for the study, Request for Free Sample Report
A grade 4 glioma brain tumor known as a glioblastoma multiforme develops from glial cells in the brain. The grade of a brain tumor describes the likelihood of the tumor's growth and dissemination. The most dangerous and aggressive sort of tumor is grade 4. The tumor's cells are aberrant, and as it spreads, the tumor develops new blood vessels. The tumor's center may develop an accumulation of dead cells (necrosis).
The glioblastoma multiforme drug market is expected to develop as a result of several factors, including the rising prevalence of glioblastoma multiforme, increased R&D, and favorable regulatory environments. During the projected period, a robust drug pipeline is anticipated to play a significant role in driving the glioblastoma multiforme drug market.
The glioblastoma multiforme treatments market is segmented by treatment, drug class, end use, and region. Based on treatment the market is segmented into chemotherapy, targeted therapy, and immunotherapy. The market is further segmented based on drug class as Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, and others. The glioblastoma multiforme treatments market is also segmented by end use as hospitals, clinics, and other centers.
To know about the assumptions considered for the study, download the pdf brochure
Based on region, the glioblastoma multiforme treatments market is segmented into North America, Europe, Asia Pacific, and Rest of the World which includes Latin America and Middle East & Africa.
Some of the major companies in the glioblastoma multiforme treatments market are Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Amgen, Inc. (US), Arbor Pharmaceuticals LLC (US), Amneal Pharmaceuticals (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.11 KEY STAKEHOLDER AND BUYING CRITERIA
6 GLIOBLASTOMA MULTIFORME DRUG MARKET, BY THERAPY, 2020-2027 (USD MILLION)
6.1 INTRODUCTION
6.2 CHEMOTHERAPY
6.5 TARGETED THERAPY
6.7 IMMUNOTHERAPY
7 GLIOBLASTOMA MULTIFORME DRUG MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
7.1 INTRODUCTION
7.2 TEMOZOLOMIDE
7.3 BEVACIZUMAB
7.4 LOMUSTINE
7.5 CARMUSTINE
7.6 OTHERS
8 GLIOBLASTOMA MULTIFORME DRUG MARKET, BY END USE, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 CLINICS
8.4 OTHERS
9 GLIOBLASTOMA MULTIFORME DRUG MARKET, BY REGION, 2020-2027 (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 ROE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 REST OF APAC
9.5 REST OF THE WORLD (ROW)
9.5.1 LATIN AMERICA
9.5.2 MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
10.4 MARKET SHARE ANALYSIS, 2021
10.5 COMPANY EVALUATION QUADRANT
10.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
10.7 COMPANY GEOGRAPHIC FOOTPRINT
10.8 COMPETITIVE SCENARIO
11 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided) *
11.1 MERCK & CO., INC.
11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
11.4 F. HOFFMANN-LA ROCHE LTD.
11.5 PFIZER, INC.
11.6 AMGEN, INC.
11.7 ARBOR PHARMACEUTICALS, LLC
11.8 AMNEAL PHARMACEUTICALS
* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS
12.7 AUTHOR DETAILS
Growth opportunities and latent adjacency in Glioblastoma Multiforme Drug Market